Gilead Sciences, Inc. is a major American biopharmaceutical company that discovers, develops, and commercializes innovative medicines. Headquartered in California, Gilead has carved out a global reputation primarily in antiviral drugs, most famously for transforming HIV/AIDS from a fatal diagnosis into a manageable chronic condition. The company made waves in the 2010s by developing a functional cure for HCV (Hepatitis C), a feat that generated astronomical profits but also sparked intense debate over drug pricing. While its historical dominance lies in virology, Gilead has been aggressively expanding into new therapeutic areas, particularly oncology (cancer treatment), through significant acquisitions. For investors, Gilead represents a fascinating case study in the high-stakes world of biotech: a company with